Mendelian randomization analysis of metabolic blood biomarkers and gastrointestinal cancer risk

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to assess the causal relationship between metabolic blood biomarkers and gastrointestinal cancer risk using Mendelian randomization.
Conducted Mendelian randomization analysis using large-scale genome-wide association study (GWAS) data.
Evaluated causal effects of metabolic blood traits on four GI cancers: gastric, colorectal, pancreatic, and gallbladder.
Applied MR-PRESSO test and Cochran's Q test for statistical robustness.
Low-density lipoprotein cholesterol inversely associated with gastric cancer risk (OR = 0.815, 95% CI: 0.703-0.946, p < 0.01).
Total cholesterol also showed protective effect against gastric cancer (OR = 0.790, 95% CI: 0.693-0.900, p < 0.01).
Higher serum uric acid levels linked with increased pancreatic cancer risk (OR = 1.246, 95% CI: 1.01-1.539, p = 0.040).

We only have this paper's title and publication details.

Explores links between metabolic blood biomarkers and GI cancer risk, suggesting preventive strategies.

No takes yet. Share an insight, caveat, or question.

Chen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share